24 Chromosome PGD is a new comprehensive chromosomal screening of embryos that examines all chromosomes for abnormalities. It appears that biopsy of the embryo on day 5 (Blastocyst stage) may give more accurate results which are not as affected by mosaicism as well as not being as detrimental to embryo growth. This technique is known as trophectoderm biopsy.
Benefits:
- 24 Chromosome Analysis examines all 24 chromosomes (all 22 non-sex chromosomes and the X and Y chromosomes) for abnormalities prior to transfer.
- This method of testing is more thorough than past methods and allows for the identification of high quality embryos for transfer.
- Embryos tested with 24 Chromosome Microarray that are determined to be normal are felt to have a much higher chance to result in a successful pregnancy.
- There is a possibility to choose the sex of the baby.
24 Chromosome Analysis PGD may be essential to patients who have:
- a history of multiple pregnancy loss,
- failed IVF attempts despite transfer of good quality embryos,
- severe male factor infertility.
